Dengue virus infection can cause debilitating dengue fever and the more severe dengue fever, previously known as dengue hemorrhagic fever. Given Advax-2’s extensive human experience in other vaccine applications, it will be pursued for further development.ĭengue fever is regarded globally as the most important arthropod-borne viral disease. Overall, Advax-2 gave the best responses just ahead of Advax-PEI. Both PIV and PsIV groups elicited different degrees of IFNγ and IL4 responses.
Spleen cells were collected on days 45 and 101 for enzyme-linked immunospot (ELISPOT) for IFNγ and IL4. For the PsIV groups, both novel adjuvants induced higher MN 50 titers than the alum control after the second dose. For the PIV groups, after one dose MN 50 titers were higher in the novel adjuvant groups compared to the alum control, while MN 50 titers were comparable between the adjuvant groups after the second dose. Neutralizing antibodies were determined by microneutralization (MN) assays, and the geometric mean 50% MN (MN 50) titers were calculated. Mice were vaccinated on days 0 and 30, and serum samples were collected on days 30, 60, 90, and 101. We tested the ability of two novel adjuvants (Advax-PEI and Advax-2), using aluminum hydroxide (alum) as control, to enhance the immunogenicity of formalin- or psoralen-inactivated (PIV or PsIV) DENV2 vaccines in mice. Currently, there is no effective vaccine that prevents infection in dengue naïve populations. Dengue fever, caused by any of four dengue viruses (DENV1-4), is a major global burden.
0 kommentar(er)
